To access this element change to forms mode OFF
Grant Award View - GA72362-V1
Application of gene-silencing nanodrugs to inhibit medulloblastoma...
GA ID:
GA72362-V1
Agency:
Cancer Australia
Approval Date:
26-Feb-2020
Variation Publish Date:
25-Feb-2022
Variation Date:
25-Feb-2022
Category:
Cancer
Grant Term:
26-Feb-2020 to 25-Oct-2023
Value (AUD):
$298,554.00
(GST inclusive where applicable)
Varies:
GA72362
- Application of gene-silencing nanodrugs to inhibit medulloblastoma growth
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 19/20 CA 19/20 Improved cancer control
Grant Program:
2019 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Application of gene-silencing nanodrugs to inhibit medulloblastoma growth
Purpose:
Brain cancer kills mre children in Australia than any other disease. The poor prognosis is due to chemoresistance and relapse. The Investigator expects to use state of the art tumour targeting nanoparticles to deliver gene silencing drugs to selectively inhibit a gene which is unregulated in brain cancer cells and promotes chemoresistance. The aim of the project is to create a new therapeutic strategy with the potential to increase survival and quality of life for children diagnosed with brain cancer.
GO ID:
GO Title:
2019 PdCCRS for funding commencing in 2020
Internal Reference ID:
1184840
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Sydney
Postcode:
5052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
5052
Country:
AUSTRALIA